The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

GOP leaders are racing to try to get the bill to the White House by July 4. The multi-trillion-dollar bill would unlock tax ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Dr. Mahsa Tehrani discusses how patients use medication to help them lose weight on 'America Reports.' ...